跳至主要内容
临床试验/NCT01272960
NCT01272960已完成不适用

Randomized, Open-label, Controlled Trial of Immediate Postpartum Versus Interval Insertion of Mirena to Increase the Usage at 6 Months After Delivery

Washington University School of Medicine1 个研究点 分布在 1 个国家目标入组 53 人开始时间: 2010年10月1日最近更新:
适应症
干预措施

试验速览

阶段
不适用
状态
已完成
入组人数
53
试验地点
1
主要终点
Mirena in Place

研究概览

简要总结

In order to determine the timing of LNG-IUS insertion that results in a greater proportion of women using the LNG-IUS at 6-months post-partum, we will perform a randomized control trial of interval versus immediate post-placenta insertion. Women will be enrolled at 36-weeks gestation and greater. At the time of vaginal delivery, women will be randomized to receive either immediate post-placenta insertion of the LNG-IUS or routine insertion at 4-8 weeks post-partum. All patients will return at 4-6 weeks post-insertion and 6 months post-partum to confirm correct position of the LNG-IUS. The primary outcome of this sub-study is the number of LNG-IUS in the correct position at 6-months. Secondary outcomes include assessing the safety of post-placental LNG-IUS insertion and difference in acceptability and symptoms experienced by participants. This is a sub-study of the Contraceptive Choice Project, a prospective cohort study that aims to improve the use of long-acting contraception by removing financial barriers which has already enrolled over 5,000 patients. Association of this study with CHOICE offers unique advantages including infrastructure to support subject recruitment, retention and completion of follow-up as well as covering the cost of LNG-IUS devices.

We hypothesize that, despite higher expulsion rates, women randomized to receive the LNG-IUS immediately after placenta delivery will have higher rates of LNG-IUS continuation due to poor rates of follow up in the interval insertion group. This is likely to be particularly noticeable in our patient population, which is largely uninsured with poor access to healthcare. Further, typical symptoms of LNG-IUS insertion include bleeding and cramping, which may be disguised by the post-partum period. Published reports of immediate post-placenta insertion focus on expulsion rates and do not report on symptoms and satisfaction rates.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Prevention
盲法
None

入排标准

年龄范围
14 Years 至 45 Years(Child, Adult)
性别
Female
接受健康志愿者
是

入选标准

  • •14-45 years
  • •Vaginal Delivery at Barnes-Jewish Hospital
  • •Sexually active with male partner
  • •No tubal ligation/hysterectomy
  • •Not currently using contraception
  • •Desire reversible contraception
  • •Reside in St. Louis City/County
  • •Requests Mirena(R) intrauterine device for contraception

排除标准

  • •Allergy to Mirena(R) system
  • •Cesarean delivery
  • •Cervical cancer, breast cancer
  • •Active liver disease
  • •Untreated cervicitis
  • •Uterine anomaly/fibroids preventing Mirena(R) placement
  • •Delivery <36 weeks
  • •Chorioamnionitis
  • •Prolonged rupture of membranes (>18 hours)

研究组 & 干预措施

Interval Insertion

Active Comparator

Will receive Mirena at 4-8 weeks post-partum after vaginal delivery.

干预措施: Interval Insertion (Device)

Post-Placental Mirena Insertion

Experimental

Will receive Mirena insertion within 10 minutes of delivery of placenta

干预措施: Post-Placenta Mirena Insertion (Device)

结局指标

主要结局

Mirena in Place

时间窗: 6 months

Proportion of women in each arm with Mirena in place at 6 months

次要结局

  • Uterine Perforation(6 months)
  • Mirena Expulsion(6 weeks)
  • Intrauterine Infection(6 months)

研究者

申办方类型
Other
责任方
Sponsor

研究点 (1)

Loading locations...

相似试验